Development of a novel Ara h 2 hypoallergen with no IgE binding or anaphylactogenic activity

BACKGROUND: To date, no safe allergen-specific immunotherapy for patients with peanut allergy is available. Previous trials were associated with severe side effects. OBJECTIVE: We sought to determine the relative importance of conformational and linear IgE-binding epitopes of the major peanut allerg...

Descripción completa

Detalles Bibliográficos
Autores principales: Tscheppe, Angelika, Palmberger, Dieter, van Rijt, Leonie, Kalic, Tanja, Mayr, Vanessa, Palladino, Chiara, Kitzmüller, Claudia, Hemmer, Wolfgang, Hafner, Christine, Bublin, Merima, van Ree, Ronald, Grabherr, Reingard, Radauer, Christian, Breiteneder, Heimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100897/
https://www.ncbi.nlm.nih.gov/pubmed/31525384
http://dx.doi.org/10.1016/j.jaci.2019.08.036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100897/
https://www.ncbi.nlm.nih.gov/pubmed/31525384
http://dx.doi.org/10.1016/j.jaci.2019.08.036

Ejemplares similares